Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer
US10478497B2 · kind B2 · utility
0Cited by
0References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 20, 2017 |
| Grant date | Nov 19, 2019 |
| Priority date | — |
| Expiry date | Jul 20, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns combinations of inecalcitol with an anti-CD38 agent such as daratumumab, MOR 202 or isatuximab for the treatment of cancer, such as hematological malignancies by increasing or inducing the expression of CD-38 by inecalcitol.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.